Title
A Study of RLS-0071 in Patients With Acute Lung Injury Due to COVID-19 Pneumonia in Early Respiratory Failure
A Randomized, Double-Blind, Placebo-Controlled, Two-Part Study to Evaluate the Safety, Tolerability, Preliminary Efficacy, PK, & PD of RLS-0071 in Patients With Acute Lung Injury Due to COVID-19 Pneumonia in Early Respiratory Failure
Phase
Phase 1Lead Sponsor
ReAlta Life Sciences, Inc.Study Type
InterventionalStatus
WithdrawnIndication/Condition
Acute Lung Injury COVID-19 ...Intervention/Treatment
rls-0071 ...Study Participants
0The aim of this study will test the safety, tolerability, and efficacy of RLS-0071 for approximately 28 days in comparison to a placebo control in patients with acute lung injury due to COVID-19 pneumonia in early respiratory failure.
Patients will be randomized and double-blinded for two parts, a single-ascending dose (SAD) part and a multiple-ascending dose (MAD) part.
The name of the study drug involved in this study is: RLS-0071.
Single dose IV infusion of 10 mg/kg RLS-0071
Single dose IV infusion of 40 mg/kg RLS-0071
The placebo control will be commercial sterile saline (0.9% Sodium Chloride Injection, United States Pharmacopoeia [USP]).
Multiple dose IV infusion of 10 mg/kg RLS-0071 administered every 8 hours for approximately 3 days (9 consecutive doses)
Multiple dose IV infusion of 40 mg/kg RLS-0071 administered every 8 hours for approximately 3 days (9 consecutive doses)
Placebo will be administered at the same volume and duration of IV infusion corresponding to the cohort dosing schedule.
Placebo will be administered at the same volume and duration of IV infusion corresponding to the cohort dosing schedule.
Inclusion Criteria: Confirmed COVID-19 based on positive SARS-CoV-2 viral RNA PCR or antigen test. Hypoxemia. Radiographic evidence of opacification consistent with viral-related pneumonia. Weight less than 150 kg. Provide written informed consent. Exclusion Criteria: Endotracheal intubation and mechanical ventilation. Noninvasive positive pressure ventilation without endotracheal intubation. Requires chronic oxygen therapy. Treatment with conventional synthetic disease-modifying antirheumatic drugs (DMARDs)/immunosuppressive agents for ≥ 4 weeks duration within 3 months prior to the Screening visit. Use of oral corticosteroids in a dose higher than prednisone 15 mg or equivalent per day for ≥ 4 weeks duration within 3 months prior to the Screening visit. Systemic autoimmune disease. Participation in any clinical research study evaluating an investigational product or therapy within 3 months prior to the Screening visit, Presence of any of the following abnormal laboratory values at Screening: absolute neutrophil count < 2,000/mm3, aspartate aminotransferase or alanine aminotransferase > 5 × upper limit of normal (ULN), platelets < 50,000/mm3. D-dimer > 2 × ULN at Screening, as evidence of potential disseminated intravascular coagulation (DIC). Has confounding medical conditions, including poorly controlled diabetes, uncontrolled New York Heart Association Class III congestive heart failure, clinically significant arrhythmias not controlled by medication, idiopathic pulmonary fibrosis, interstitial lung disease, or chronic obstructive pulmonary disease. Has bacterial sepsis currently or suspicion thereof. Has cancer currently and is receiving active treatment (including radiation therapy or chemotherapy) or malignancy within the last 5 years, with the exception of curable cancer (eg, basal or squamous cell skin cancer, cervical cancer in situ, nonmedullary thyroid carcinoma) that has been adequately treated (eg, excision). Prior history of myocardial infarction or angina, stroke or transient ischemic attack (TIA), pulmonary embolism or deep vein thrombosis. Is moribund and not expected to survive 48 hours following Screening or for whom no further aggressive treatment such as mechanical ventilation is planned.
